...
首页> 外文期刊>Pathology oncology research: POR >Metallothionein 3 Expression in Normal Skin and Malignant Skin Lesions
【24h】

Metallothionein 3 Expression in Normal Skin and Malignant Skin Lesions

机译:金属硫蛋白3在正常皮肤和恶性皮肤病变中的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Metallothionein-3 (MT-3) has been shown to be expressed in several malignancies and to have an impact on patients' survival in breast and urinary bladder cancer cases. However, its expression has not been determined in normal skin or in its malignant lesions. MT-3 expression was studied using immunohistochemistry in 17 cases of normal skin, 18 of actinic keratosis (AK), 39 of squamous cell carcinoma (SCC), and 23 of basal cell carcinoma (BCC). Low MT-3 expression was observed in normal skin epidermis with faint or no expression in the epidermis basal layer. Significantly higher MT-3 expression was noted in AK (P = 0.007) and SCC (P < 0.0001), as compared with normal skin epidermis. BCC cases were characterized by the lowest MT-3 expression of all the examined groups, which was significantly lower in comparison to normal skin epidermis, AK, and SCC (P = 0.009; P < 0.0001 and P < 0.0001, respectively). In conclusion, MT-3 may be involved in the development of SCC.
机译:金属硫蛋白3(MT-3)已被证明在多种恶性肿瘤中表达,并且对乳腺癌和膀胱癌患者的生存产生影响。然而,尚未在正常皮肤或其恶性病变中确定其表达。使用免疫组织化学研究了17例正常皮肤,18例光化性角化病(AK),39例鳞状细胞癌(SCC)和23例基底细胞癌(BCC)的MT-3表达。在正常皮肤表皮中观察到MT-3表达低,在表皮基底层中表达微弱或没有表达。与正常皮肤表皮相比,在AK(P = 0.007)和SCC(P <0.0001)中发现MT-3表达明显更高。 BCC病例的特征是所有检查组的MT-3最低表达,与正常皮肤表皮,AK和SCC相比明显降低(分别为P = 0.009,P <0.0001和P <0.0001)。总之,MT-3可能参与了SCC的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号